Who is sponsoring NCT06409949?

NCT06409949 is sponsored by University of Nebraska.

What drugs are being tested in NCT06409949?

Interventions in NCT06409949: Walking assessment, QOL Survey, Ankle pressure at rest and after stress, Muscle Oxygen, Serum MitoQ Level, Needle Biopsy.

What condition does NCT06409949 study?

NCT06409949 studies Peripheral Arterial Disease.

Is NCT06409949 still recruiting?

NCT06409949 is currently recruiting now. Last updated 21 February 2026.

Last reviewed 2026-02-21 · How we verify

NCT06409949

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology

Recruiting now NA Last updated 21 February 2026

What this trial tests

NA trial testing Walking assessment in Peripheral Arterial Disease in 60 participants. Currently enrolling.

Timeline

1 June 2023

Primary endpoint
1 October 2026

1 June 2027

Quick facts

Lead sponsor	University of Nebraska
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	60
Start date	1 June 2023
Primary completion	1 October 2026
Estimated completion	1 June 2027
Sites	1 location across United States

Drugs / interventions tested

Walking assessment
QOL Survey
Ankle pressure at rest and after stress
Muscle Oxygen
Serum MitoQ Level
Needle Biopsy

Conditions studied

Peripheral Arterial Disease — all drugs for Peripheral Arterial Disease →

Sponsor

University of Nebraska

Who can join

21 and older, any sex, with Peripheral Arterial Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Walking Impairment: maximum treadmill distance
Time frame: Before and After 6 months of treatment with MitoQ or placebo
Evaluation of maximum walking distance on treadmill until participant chooses to stop due to pain in his legs.

Sponsor's own description

In our research, we are delving into whether taking MitoQ for six months can improve the symptoms and function of people diagnosed with peripheral artery disease, especially those who suffer from leg pain while walking, known as intermittent claudication. We will be checking if MitoQ helps people with claudication walk better, be more active every day, feel better about their lives, and if it enhances the health of their leg muscles.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Mitochondria-targeted nanotechnology in cardiovascular diseases: a review of recent advances.
Sun S, Wu M, Zhang P, Sun L, et al · · 2026 · PMID 42022751 · DOI 10.1093/rb/rbag040

Verify or expand the search:

Other recruiting trials for Peripheral Arterial Disease

Currently open trials in the same condition.

NCT05437562 — Randomized Clinical Trial for Ewing Amputation in the VA · NA · recruiting
NCT07427108 — Road Mapping Guided Puncture Versus Ultrasound Guided Puncture During Retrograde Angioplasty Feasibility and Safety · NA · recruiting
NCT07336381 — Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy · NA · recruiting
NCT07076082 — Vascular Trial Associated Registry Pilot · Phase 4 · recruiting
NCT06308562 — Fuzzy Wale Compression Stockinet to Promote Healing Following Transtibial Amputation for Peripheral Arterial Disease · NA · recruiting

Other University of Nebraska trials

Trials by the same sponsor.

NCT07507006 — Feasibility Study of the Flash-Sole: A Wearable Midsole With Soft Actuators for Walking Assistance · NA · not yet recruiting
NCT07517705 — MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma · NA · not yet recruiting
NCT07506993 — Inflammation in Clear Aligners With and Without Attachments · not yet recruiting
NCT07207850 — Parents Helping Parents for Youth Vaping Cessation · NA · not yet recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06409949 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Nebraska
Last refreshed: 21 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06409949.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing